# Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

> **NCT02206425** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oncotherapeutics** · enrollment: 45 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **DIETARY_SUPPLEMENT:** Ascorbic acid
- **DRUG:** PLD
- **DRUG:** Lenalidomide
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT02206425
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2018-01-19
- **Final completion:** 2018-03-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206425, "Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02206425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*